Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR)

Cell Cycle

Volumn 12, Issue 21, 2013, Pages 3421-3432

  Garbers, Christoph ^a   Kuck, Fabian ^a   Aparicio Siegmund, Samadhi ^a   Konzak, Kirstin ^a   Kessenbrock, Mareike ^a   Sommerfeld, Annika ^b   Häussinger, Dieter ^b   Lang, Philipp A ^b   Brenner, Dirk ^c,d   Mak, Tak W ^c   Rose John, Stefan ^e   Essmann, Frank ^f   Schulze Osthoff, Klaus ^f   Piekorz, Roland P ^a   Scheller, Jürgen ^a  

^a Department of Orthopedic Surgery   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

EGFR; Interleukin 6; Interleukin 6 receptor; mTOR; SASP; Senescence

Indexed keywords

ADAM10 ENDOPEPTIDASE; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CELL AGING; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HETEROZYGOSITY; IN VIVO STUDY; LIVER CELL; MALE; MITOSIS SPINDLE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

EGFR; INTERLEUKIN 6; INTERLEUKIN 6-RECEPTOR; MTOR; SASP; SENESCENCE;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CARRIER PROTEINS; CELL AGING; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, INTERLEUKIN-6; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84887866778     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26431     Document Type: Article

References (55)

1. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88; PMID:21296109; http://dx.doi.org/10.1016/j.bbamcr.2011.01.034
2. Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 2012;23:85-97; PMID:22595692; http://dx.doi.org/10.1016/j.cytogfr.2012.04.001
3. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol 2011;90:484-94; PMID:21145125; http://dx.doi.org/10.1016/j.ejcb.2010. 10.007
4. Garbers C, Scheller J. Interleukin-6 and interleukin-11: same same but different. Biol Chem 2013;394:1145-61; PMID:23740659; http://dx.doi.org/10.1515/ hsz-2013-0166
5. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83; PMID:21881215; http://dx.doi.org/10.1172/JCI57158
6. Matthews V, Schuster B, Schütze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen KJ, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278:38829-39; PMID:12832423; http://dx.doi.org/10.1074/jbc. M210584200 (Pubitemid 37221782)
7. Garbers C, Jänner N, Chalaris A, Moss ML, Floss DM, Meyer D, Koch-Nolte F, Rose-John S, Scheller J. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem 2011;286:14804-11; PMID:21454673; http://dx.doi.org/10.1074/jbc. M111.229393
8. Rose-John S, Schooltink H, Lenz D, Hipp E, Dufhues G, Schmitz H, Schiel X, Hirano T, Kishimoto T, Heinrich PC. Studies on the structure and regulation of the human hepatic interleukin-6 receptor. Eur J Biochem 1990;190:79-83; PMID:2163835; http://dx.doi.org/10.1111/j.1432-1033.1990.tb15548.x (Pubitemid 20183967)
9. Snyers L, De Wit L, Content J. Glucocorticoid upregulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci U S A 1990;87:2838-42; PMID:2157217; http://dx.doi.org/10.1073/pnas.87.7. 2838
10. Ladenburger A, Seehase M, Kramer BW, Thomas W, Wirbelauer J, Speer CP, Kunzmann S. Glucocorticoids potentiate IL-6-induced SP-B expression in H441 cells by enhancing the JAK-STAT signaling pathway. Am J Physiol Lung Cell Mol Physiol 2010;299:L578-84; PMID:20693312; http://dx.doi.org/10.1152/ajplung. 00055.2010
11. Dittrich A, Khouri C, Sackett SD, Ehlting C, Böhmer O, Albrecht U, Bode JG, Trautwein C, Schaper F. Glucocorticoids increase interleukin-6- dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor. Hepatology 2012;55:256-66; PMID:21898505; http://dx.doi.org/10.1002/hep. 24655
12. Liao W, Lin J-X, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 2011;12:551-9; PMID:21516110; http://dx.doi.org/10.1038/ni.2030
13. Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013;32:3071-9; PMID:22824797
14. Libertini SJ, Chen H, Al-Bataina B, Koilvaram T, George M, Gao AC, Mudryj M. The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate 2012;72:649-60; PMID:21837779; http://dx.doi.org/10.1002/pros.21468
15. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118; PMID:20078217; http://dx.doi.org/10.1146/annurev- pathol-121808-102144
16. Ohtani N, Takahashi A, Mann DJ, Hara E. Cellular senescence: a double-edged sword in the fight against cancer. Exp Dermatol 2012;21(Suppl 1):1-4; PMID:22626462; http://dx.doi.org/10.1111/j.1600-0625.2012.01493.x
17. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, Van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31; PMID:18555778; http://dx.doi.org/10.1016/j.cell.2008.03.039 (Pubitemid 351787746)
18. Schmidt S, Essmann F, Cirstea IC, Kuck F, Thakur HC, Singh M, Kletke A, Jänicke RU, Wiek C, Hanenberg H, et al. The centrosome and mitotic spindle apparatus in cancer and senescence. Cell Cycle 2010;9:4469-73; PMID:21088502; http://dx.doi.org/10.4161/cc.9.22.13684
19. Blagosklonny M V. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012;4:159-65; PMID:22394614
20. Leontieva OV, Lenzo F, Demidenko ZN, Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle 2012;11:4642-9; PMID:23187803; http://dx.doi.org/10.4161/cc.22937
21. Kolesnichenko M, Hong L, Liao R, Vogt PK, Sun P. Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 2012;11:2391-401; PMID:22627671; http://dx.doi.org/10.4161/cc.20683
22. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev 2013;23:53-62; PMID:23317514; http://dx.doi.org/10.1016/j.gde. 2012.12.005
23. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch GJ Jr., Klocker H, Bartsch G, Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol 2000;191:239-44; PMID:10878544; http://dx.doi.org/10.1002/1096-9896 (2000) 9999:9999<::AID-PATH633>3.0. CO;2-X (Pubitemid 30441246)
24. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003;22:7809-18; PMID:14586407; http://dx.doi.org/10.1038/sj.onc.1207084 (Pubitemid 37485540)
25. Noda M, Yamakawa Y, Matsunaga N, Naoe S, Jodoi T, Yamafuji M, Akimoto N, Teramoto N, Fujita K, Ohdo S, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci 2012;14:515-26; PMID:23271367; http://dx.doi.org/10.3390/ijms14010515
26. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786-8; PMID:2253221
27. Garcia-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 2005;47:82-9; PMID:15982327; http://dx.doi.org/10.1111/j.1365-2559.2005.02178.x (Pubitemid 40978817)
28. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56; PMID:18060032; http://dx.doi.org/10.1172/JCI31871 (Pubitemid 350224094)
29. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96; PMID:22473468
30. Schmidt S, Schneider L, Essmann F, Cirstea IC, Kuck F, Kletke A, Jänicke RU, Wiek C, Hanenberg H, Ahmadian MR, et al. The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene 2010;29:6184-92; PMID: 20729911; http://dx.doi.org/10.1038/onc.2010.354
31. Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny M V. Rapamycin decelerates cellular senescence. Cell Cycle 2009;8:1888-95; PMID:19471117; http://dx.doi.org/10.4161/cc.8.12.8606
32. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77:400-10; PMID:20130423; http://dx.doi.org/10.1159/000279388
33. Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, Heinrich PC, Rose-John S. Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J 1991;277:659-64; PMID:1872801
34. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012;13:283-96; PMID:22473468
35. Cichowski K, Hahn WC. Unexpected pieces to the senescence puzzle. Cell 2008;133:958-61; PMID:18555773; http://dx.doi.org/10.1016/j.cell.2008.05.027 (Pubitemid 351787750)
36. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, Van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31; PMID:18555778; http://dx.doi.org/10.1016/j.cell.2008.03.039 (Pubitemid 351787746)
37. Yun UJ, Park SE, Jo YS, Kim J, Shin DY. DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett 2012;323:155-60; PMID:22521547; http://dx.doi.org/10. 1016/j.canlet.2012.04.003
38. Dulic V. Senescence regulation by mTOR. Methods Mol Biol 2013;965:15-35; PMID:23296649; http://dx.doi.org/10.1007/978-1-62703-239-1-2
39. Gerhartz C, Dittrich E, Stoyan T, Rose-John S, Yasukawa K, Heinrich PC, Graeve L. Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur J Biochem 1994;223:265-74; PMID:8033901; http://dx.doi.org/10.1111/j.1432-1033.1994.tb18991.x (Pubitemid 24221671)
40. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011;15:63-74; PMID:21110697; http://dx.doi.org/10.1517/14728222.2011.541440
41. Rose-John S, Mitsuyama K, Matsumoto S, Thaiss WM, Scheller J. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des 2009;15:2095-103; PMID:19519447; http://dx.doi.org/10.2174/138161209788489140
42. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13; PMID:19185845; http://dx.doi.org/10.1016/j.ccr.2009.01.001
43. Thiem S, Pierce T P, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, et al. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013;123:767-81; PMID:23321674
44. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40; PMID:20713723; http://dx.doi.org/10. 1073/pnas.1009472107
45. Chang J, Burkett PR, Borges CM, Kuchroo VK, Turka LA, Chang CH. MyD88 is essential to sustain mTOR activation necessary to promote T helper 17 cell proliferation by linking IL-1 and IL-23 signaling. Proc Natl Acad Sci U S A 2013;110:2270-5; PMID:23341605; http://dx.doi.org/10.1073/pnas.1206048110
46. Alexander E, Hildebrand DG, Kriebs A, Obermayer K, Manz M, Rothfuss O, Schulze-Osthoff K, Essmann F. IκBζ is a regulator of the senescence-associated secretory phenotype in DNA damageand oncogene-induced senescence. J Cell Sci 2013;126:3738-45; PMID:23781024; http://dx.doi.org/10. 1242/jcs.128835
47. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003;102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775 (Pubitemid 36988021)
48. Ludwig A, Hundhausen C, Lambert MH, Broadway N, Andrews RC, Bickett DM, Leesnitzer MA, Becherer JD. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005;8:161-71; PMID:15777180; http://dx.doi.org/10.2174/1386207053258488 (Pubitemid 40388743)
49. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992;149:2021-7; PMID:1381393
50. Suzuki A, De La Pompa JL, Stambolic V, Elia AJ, Sasaki T, Del Barco Barrantes I, Ho A, Wakeham A, Itie A, Khoo W, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78; PMID:9799734; http://dx.doi.org/10.1016/ S0960-9822 (07) 00488-5 (Pubitemid 28494715)
51. Stambolic V, Suzuki A, De La Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39; PMID:9778245; http://dx.doi.org/10.1016/S0092-8674 (00) 81780-8 (Pubitemid 28458022)
52. Reinehr R, Graf D, Fischer R, Schliess F, Häussinger D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. Hepatology 2002;36:602-14; PMID:12198652; http://dx.doi.org/10.1053/jhep. 2002.35447 (Pubitemid 34977170)
53. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Wetzel W, Schulze-Osthoff K, Nürnberg B, Piekorz R P. The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J Biol Chem 2007;282:29273-83; PMID:17675670; http://dx.doi.org/10.1074/jbc. M704151200 (Pubitemid 350043368)
54. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, Jones SA, Rose-John S, Scheller J. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007;110:1748-55; PMID:17567983; http://dx.doi.org/10.1182/blood-2007-01- 067918 (Pubitemid 47443884)
55. Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Grötzinger J, Jones SA, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130(sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011;286:42959-70; PMID:21990364; http://dx.doi.org/10.1074/jbc. M111.295758